congresses-banner
The content contained is subject
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
congresses-tab
PublicationView
Poster
Edoxaban
ESC 2024 | August 30 – September 2, 2024
Association of R2-CHA2DS2-VASc score and clinical outcomes after bioprosthetic valve replacement:
Subanalysis from BPV-AF registry
Poster
Edoxaban
ESC 2024 | August 30 – September 2, 2024
Clinical outcomes of edoxaban treatment in atrial fibrillation patients with high bleeding risk:
Insights from the ETNA-AF-China 1-Year follow-up
Poster
Edoxaban
ESC 2024 | August 30 – September 2, 2024
Edoxaban dose, frailty, and outcomes in patients with atrial fibrillation: The ETNA-AF-Europe 4-year follow-up
Poster
Edoxaban
ESC 2024 | August 30 – September 2, 2024
Edoxaban for stroke prevention in routine practice patients with atrial fibrillation with and without atherosclerotic disease: A post hoc sub-study of ETNA-AF-Europe
Poster
Edoxaban
ESC 2024 | August 30 – September 2, 2024
Impact of body weight and body mass index on clinical outcomes of edoxaban therapy in atrial fibrillation patients included in the Global ETNA-AF programme
Poster
Edoxaban
ESC 2024 | August 30 – September 2, 2024
Impact of differences in body mass index, body surface area and lean body mass on clinical outcomes in patients with atrial fibrillation receiving edoxaban: 4-year follow-up data from ETNA-AF-Europe
Poster
Edoxaban
ESC 2024 | August 30 – September 2, 2024
Low rates of haemorrhagic stroke, not increased by age, renal/hepatic impairment, concomitant anti-platelet use and high CHA2DS2-VASc scores, in the 4-year follow-up of ETNA-AF-Europe
Poster
Edoxaban
ESC 2024 | August 30 – September 2, 2024
Persistence and predictors for non-persistence to edoxaban therapy in patients with atrial fibrillation: 4-year follow-up data from the ETNA-AF-Europe study